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Introduction
Extracellular signal-regulated kinases (ERKs) are members of 
the MAPK family of signaling proteins, which play a crucial 
role in the intracellular transmission of extracellular signals 
(Seger and Krebs, 1995; Yoon and Seger, 2006). Induction of 
this signaling cascade leads to phosphorylation of several target 
proteins that eventually regulate proliferation and other cellular 
processes (Yoon and Seger, 2006). The ERK-induced prolifera-
tion is regulated by a multistep mechanism that involves several 
cell-cycle stages (Zhang and Liu, 2002), including the regula-
tion of G0, G1, S, and M (Tamemoto et al., 1992; Lavoie et al., 
1996; Wright et al., 1999; Zhang and Liu, 2002; Edmunds and 
Mahadevan, 2004). Thus, aside from its role in the acute trans-
mission of extracellular signals, the ERK cascade plays a role in 
the regulation of other cellular processes, which are mediated 
via a large set of effectors (Yoon and Seger, 2006).
One role of the ERK cascade is the regulation of G2/M and 
mitosis progression. Indeed, all components of the cascade were 
shown to undergo activation during the late G2 and M phases 
of the cell cycle (Tamemoto et al., 1992; Edelmann et al., 1996; 
Shapiro et al., 1998). In addition, inhibition of MEKs’ activities 
by dominant-negative constructs or with pharmacological in-
hibitors delayed the progression of cells through the same stages 
(Wright et al., 1999; Roberts et al., 2002). Several molecular 
mechanisms have been implicated in the regulation of G2/M by 
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the ERK cascade, including the phosphorylation of centromere 
protein E (Zecevic et al., 1998), SWI–SNF (Sif et al., 1998), and 
polo-like kinase 3 (Plk3) (Xie et al., 2004), as well as the indirect 
activation of Plk1, Cdc2 (Liu et al., 2004), and Myt1 (Palmer 
et al., 1998). However, one of the best studied mechanisms by 
which the cascade can infl  uence mitosis is the regulation of 
Golgi fragmentation, which is the focus of this study.
During mitosis, a mammalian cell needs to split its Golgi 
apparatus between two daughter cells. The mechanism that al-
lows the proper division to occur is a massive fragmentation of 
the Golgi into thousands of vesicles that are later shared by the 
splitting cells (Shorter and Warren, 2002; Colanzi et al., 2003). 
This process occurs during the prophase/anaphase stages of mi-
tosis, and is essential for the proper progression of cell division 
(Sutterlin et al., 2002). One of the kinases that participates in 
the regulation of this process is MEK1 (Acharya et al., 1998), 
which normally acts as an activator of ERK1 and ERK2 
(ERK1/2; Yoon and Seger, 2006). Interestingly, these ERKs 
were not found to be associated with the fragmented Golgi. 
In addition, it was later shown that MEK action in the Golgi can 
proceed even in the absence of their NH2-terminal D domain, 
which is essential for their activity toward ERK1/2 (Chuderland 
and Seger, 2005), indicating the presence of a different MEK 
substrate in the Golgi (Colanzi et al., 2000).
In recent years, several MEK1-induced, ERK1/2-
independent  proteins were proposed to play a role in mitotic Golgi 
fragmentation, including an ERK-like protein (Acharya et al., 1998) 
that appears to be mono-Tyr phosphorylated before fragmenta-
tion (Cha and Shapiro, 2001). The mono-Tyr phosphorylation   
of the ERK-like protein suggests that its mode of regulation 
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xtracellular signal-regulated kinase 1c (ERK1c) is 
an alternatively spliced form of ERK1 that is regu-
lated differently than other ERK isoforms. We stud-
ied the Golgi functions of ERK1c and found that it plays 
a role in MEK-induced mitotic Golgi fragmentation. Thus, 
in late G2 and mitosis of synchronized cells, the expres-
sion and activity of ERK1c was increased and it colocal-
ized mainly with Golgi markers. Small interfering RNA of 
ERK1c signiﬁ   cantly attenuated, whereas ERK1c over-
expression facilitated, mitotic Golgi fragmentation. These 
effects were also reﬂ  ected in mitotic progression, indicat-
ing that ERK1c is involved in cell cycle regulation via 
  modulation of Golgi fragmentation. Although ERK1 was 
activated in mitosis as well, it could not replace ERK1c in 
regulating Golgi fragmentation. Therefore, MEKs regulate 
mitosis via all three ERK isoforms, where ERK1c acts spe-
ciﬁ  cally in the Golgi, whereas ERK1 and 2 regulate other 
mitosis-related processes. Thus, ERK1c extends the speci-
ﬁ   city of the Ras-MEK cascade by activating ERK1/2-
  independent processes.JCB • VOLUME 172 • NUMBER 6 • 2006  886
is distinct from that of ERK1/2, which are usually found either 
nonphosphorylated, under resting conditions, or double Thr and 
Tyr phosphorylated, upon activation (Yoon and Seger, 2006). 
The mechanism by which the ERK-like kinase executes MEKs’ 
signals in the Golgi is not fully understood, but may involve phos-
phorylation of the Golgi reassembly stacking protein of 55 kD,
which serves as an ERK2 substrate in the Golgi (Jesch et al., 
2001), or activation of Plk3, which was recently proposed to 
mediate MEK1 signals in the Golgi (Xie et al., 2004). It should 
be noted, however, that the exact role of MEKs and their sub-
strates in Golgi fragmentation is controversial, as it was shown 
that the phosphorylation of GM130, which is an important com-
ponent of this process, mainly requires the activity of CDC2 
without the involvement of MEKs (Lowe et al., 1998; Shorter 
and Warren, 2002; Uchiyama et al., 2003). Therefore, this study 
may provide new information on this controversial issue.
Recently, we cloned an alternatively spliced isoform of 
ERK1 in human cells and named it ERK1c (Aebersold et al., 
2004). This ERK isoform is regulated differently from ERK1/2, 
mainly because of its altered cytosolic retention sequence/com-
mon docking motif. In addition, it was shown that it is localized 
in the Golgi of confl  uent cells and that its localization is regu-
lated mainly by monoubiquitination (Aebersold et al., 2004). 
We extended our studies on the Golgi function of ERK1c, and 
found that its expression, phosphorylation, activity, and Golgi 
localization are increased in mitosis. Knockdown experiments 
revealed that ERK1c attenuates Golgi fragmentation during mi-
tosis, and as a consequence it slows down cell cycle progression. 
Similar to the situation in high density cell culture, the ERK1c 
effect could not be substituted by ERK1 or ERK2, making it a 
unique MEK effector in mitosis. These results suggest that 
ERK1c mediates the MEK-regulated Golgi fragmentation dur-
ing mitosis. In addition, this unique role of ERK1c provides a 
molecular mechanism by which ERK cascade may execute its 
multiple distinct, and even opposing, effects.
Results
ERK1c expression and activity 
are elevated during mitosis
Golgi fragmentation in mitosis is regulated by several pro-
tein kinases, including MEKs (Colanzi et al., 2003). Because 
ERK1/2, which are the known downstream targets of MEKs, 
are probably not involved in this Golgi fragmentation (Acharya 
et al., 1998), the mechanisms by which MEKs regulate this 
  process are not clear. Recently, we identifi  ed ERK1c, which is 
an ERK1 isoform, and showed that it is localized in the Golgi 
of cells from high density cultures (Aebersold et al., 2004). 
Therefore, we undertook an examination of whether ERK1c 
plays a role in mitosis-related, MEK-dependent Golgi fragmen-
tation. To do so, we synchronized HeLa cells using the double 
thymidine block procedure (Merrill, 1998), which arrests cells 
in early S phase and allows a synchronized cell cycle progres-
sion upon block release. Indeed, most of the cells were in 
S phase shortly after the release, shifted to G2 within 6–9 h, and 
cycled back to the next G1 within 12 h (Fig. 1 A).  These results 
were complemented by mitotic index determination, in which 
we found that the mitosis of the synchronized cells peaked 
11 h after release (Fig. 1 B and Fig. S1, available at http://www.
jcb.org/cgi/content/full/jcb.200509063/DC1). We then exam-
ined the behavior of ERK1c, as compared with ERK1 in the 
synchronously cycling cells, 6 h (G2), 9 h (late G2), and 11 h 
(peak mitosis) after release. The expression levels of ERK1c, 
which were obtained by blotting with specifi  c ERK1c antibody, 
were signifi  cantly increased during mitosis (Fig. 1 C). The ap-
parent lower levels of ERK1c in S and G2 cells, as compared 
with the nonsynchronized cells, were probably attributable to 
the observation that in the latter cells the expression of ERK1c 
was the mean between the low amount in S phase and the much 
higher amount in mitosis. On the other hand, the expression 
levels of ERK1/2 were unchanged during the times examined, 
although the regulatory phosphorylation of the ERKs, which 
was determined using diphospho-ERK (pERK) antibody (Yao 
et al., 2000), was elevated in late G2 and during mitosis, sup-
porting previous works that demonstrated activation of MEKs 
and ERK1/2 during these stages of the cell cycle (Wright et al., 
1999; Roberts et al., 2002).
Because ERK1c migrates together with ERK2 on an SDS-
PAGE (Aebersold et al., 2004), it was not clear from the results 
whether the 42-kD band recognized by the pERK antibody con-
tained any phosphorylated ERK1c or consisted only of phos-
phorylated ERK2, which is much more abundant. Therefore, to 
follow the specifi   c activation of ERK1c and compare it to 
ERK1, these two proteins were immunoprecipitated with either 
specifi  c ERK1c or ERK1 antibodies and subjected to an in vitro 
kinase assay using myelin basic protein (MBP) as a substrate. 
Using this protocol, nonsynchronous cells were found to con-
tain relatively low ERK1c activity and even lower ERK1 activ-
ity (Fig. 1 D). The activity of ERK1c was lower in the S and G2 
phases and signifi  cantly increased during late G2 and mitosis 
(sevenfold at 11 h). This rate of activation was different from 
that of ERK1, which constantly increased throughout the ex-
periment, up to 12-fold higher than its activity in S phase. 
  Because the increased activity of ERK1c could be caused by its 
elevated expression, we equilibrated the amount of ERK1c pro-
tein from nonsynchronized and mitotic cells to measure changes 
in their specifi  c activity. Elevated levels of pERK1c were de-
tected in the mitotic cells as compared with the nonsynchronous 
cells (Fig. 1 E), indicating that the elevation of ERK1c activity 
in mitosis is achieved by elevation in its expression, as well as 
in its activatory Thr and Tyr phosphorylation.
To eliminate the possibility that ERK1c activation was in-
duced by the thymidine treatments and not by cell cycle pro-
gression, we used nocodazole, which arrests cells in mitosis via 
a distinct mechanism (Merrill, 1998). Indeed, application of 
  nocodazole to HeLa cells resulted in their mitotic arrest within 
24 h, as judged by FACS analysis (Fig. 2 A) and mitotic index 
determination (not depicted).  The treated cells were then used 
to examine the expression and activation of ERK1c and ERK1 
in a manner similar to that described for the double thymidine–
based synchronization. Thus, similar to the double thymidine 
results, ERK1c expression, as well as its phosphorylation and 
activity, were elevated in the nocodazole- arrested cells (Fig. 2, 
B and C). On the other hand, in agreement with a previous study MITOTIC GOLGI FRAGMENTATION IS REGULATED BY ERK1C • SHAUL AND SEGER 887 
(Takenaka et al., 1998), the expression of ERK1 was not af-
fected, and the activity of this protein was only slightly elevated 
by the nocodazole treatment, suggesting a specifi  c mode of 
ERK1c activation in these stages of mitosis. Collectively, our 
results clearly show that both the expression and activity of 
ERK1c are elevated by cell cycle progression and not by indi-
vidual chemical treatments.
ERK1c is colocalized with Golgi markers 
during the early stages of mitosis
In a previous study, we showed that ERK1c resides in the Golgi 
of confl  uent cells (Aebersold et al., 2004); therefore, we under-
took to examine whether ERK1c can be localized in the Golgi 
apparatus during mitosis as well. To do so, the double thymidine –
synchronized mitotic HeLa cells were costained with ERK1c, 
together with either the general Golgi marker GM130 or the 
cis-Golgi marker p58 antibodies. The exact stage of mitosis 
was determined by DAPI staining, which showed a typical 
chromosomal arrangement for each phase and confi  rmed that 
the sample depicted 11 h after the release from the thymidine 
block contained mainly cells ranging from late G2 to telophase. 
The staining of these cells with the Golgi markers (Fig. 3) re-
vealed the expected (Colanzi et al., 2003) two-step fragmenta-
tion, fi  rst into bulbs (prophase and early prometaphase) and 
later into microvesicles (late prometaphase and metaphase), 
which were spread throughout the cell. 
We then followed ERK1c localization in the various stages 
of mitosis (Fig. 3 A). In interphase cells, ERK1c was diffusely 
spread throughout the cells, without any Golgi preferences. 
In prophase, which is when the DNA started to condense, much 
of the ERK1c staining was found colocalized with the partially 
fragmented Golgi in the perinuclear region, although some 
ERK1c remained spread throughout the cells. In prometaphase, 
when the DNA was already condensed and on its way to the 
equator, ERK1c was mostly colocalized with the Golgi markers 
in some bulbs and microvesicles that covered a signifi  cant por-
tion of the cytosol. In metaphase, when the condensed DNA was 
localized in the cell equator, both ERK1c and the Golgi markers   
were homogenously spread throughout the cells; similar dis-
tribution was also observed with the mitotic nocodazole-
arrested cells (not depicted). Interestingly, during telophase there 
was still interaction of ERK1c with the recomposing Golgi, as 
well as with the kinetochore (Fig. 3 B), but this colocalization 
was rapidly changed, and in new G1 cells ERK1c was again 
diffusely spread. The observation that ERK1c is concentrated 
Figure 1.  Elevated ERK1c expression, phosphorylation, and activity in 
mitosis. HeLa cells were either synchronized by double thymidine arrest, 
which was followed by the removal of the block to enable cell cycle pro-
gression, or left untreated (NS, nonsynchronized) as a control. (A) Repre-
sentative ﬂ  ow cytometry analysis of the synchronized HeLa cells. At the 
indicated times after the block release, the cells were ﬁ  xed, stained with 
propidium iodide, and analyzed by ﬂ   ow cytometry to determine the 
amount of DNA per cell (2N and 4N). (B) Mitotic index determination. The 
tested cells were ﬁ  xed and stained with DAPI. The percentage of mitotic 
cells out of the total number of nuclei counted is presented as the means ± 
SEM of three experiments. n = 300. (C) ERK1c expression is elevated in 
the G2/M phase of the cell cycle. The tested cells were   harvested and sub-
jected to a Western blot with ERK1c, ERK1/2, and pERK antibodies. 
(D) ERK1c activity is enhanced in the G2/M phase of the cell cycle. The tested
cells were harvested and ERK1 or ERK1c were immunoprecipitated using 
their respective antibodies. The immunoprecipitated   proteins were either 
subjected to an in vitro kinase assay using MBP as a substrate (ERK1c and 
ERK1 act.) or detected with ERK1c and ERK1 antibodies. Coomassie blue 
staining of the phosphorylated MBP is shown to   conﬁ  rm equal amounts of 
substrate. (E) The diphosphorylation of ERK1c is elevated during mitosis. 
Synchronized HeLa at mitosis (M) or untreated cells (N) were harvested, 
followed by immunoprecipitation of their ERK1c using ERK1c antibody. 
Equal amounts of ERK1c (predetermined by Western blotting) were sub-
jected to Western blots with pERK or ERK1c antibodies.JCB • VOLUME 172 • NUMBER 6 • 2006  888
in the Golgi in the various stages of mitosis was also confi  rmed 
by costaining with lamin, which is disassembled together with 
the entire nuclear envelope after prophase (Fig. S2, available 
at http://www.jcb.org/cgi/content/full/jcb.200509063/DC1). 
It should also be noted that the Golgi localization was specifi  c   
to ERK1c, as the more abundant ERK1 isoform was not detected 
in the Golgi during prophase (Fig. 3 C) or any other stage of the 
cell cycle. The colocalization of ERK1c with p58 or GM130 
was confi  rmed by an electronic merge of the two stainings, 
showing again that the major portion of ERK1c is colocalized 
with the Golgi markers that are already in prophase (Fig. S3). 
Quantifi  cation of mitotic cells (prophase/telophase) revealed 
costaining of ERK1c and the Golgi markers in  75% of the 
cells as compared with only  23% in interphase cells (Fig. 3 D). 
However, it is possible that the percentage of mitotic cells with 
Golgi-localized ERK1c is even higher because cells in which 
the Golgi or the ERK1c were not properly stained were not 
counted as ERK1c-Golgi–colocalized cells. These results indi-
cate that ERK1c specifi  cally interacts with the Golgi in mitosis 
and not only upon an elevation in cell density.
Monophosphorylation of ERK1c 
downstream of MEKs in the Golgi
We have previously shown that, similar to ERK1/2, ERK1c can 
be activated by the upstream MEK kinases (Aebersold et al., 
2004). However, the different kinetics of ERK1c and ERK1 ac-
tivation during the cell cycle (Fig. 1) challenged the involvement 
of MEKs in ERK1c activation; therefore, it was important to 
examine whether ERK1c is directly activated by MEKs in the 
mitotic Golgi. For this purpose we fi  rst overexpressed a con-
stitutively active (CA) form of MEK1 (Jaaro et al., 1997) or 
added the MEK inhibitor PD98059 to synchronized G2/M HeLa 
cells. Immunoprecipitation of ERK1c from the treated cells, 
followed by an in vitro kinase assay, revealed that ERK1c was 
highly activated in the mitotic cells containing CA-MEK1 and 
that its activation was reduced with PD98059 (Fig. 4 A).  These 
activations correlated with the double-Thr and -Tyr phosphor-
ylation of ERK1c, again indicating that ERK1c is a substrate 
for MEK1 during mitosis. In addition, ERK1c appeared to be 
heavily mono-Tyr phosphorylated in the mitotic cells, and this 
monophosphorylation was increased in the mitotic cells express-
ing the CA-MEK and prevented by PD98059 (Fig. 4 A). This 
phosphorylation was distinct from that of ERK1/2, which were 
mainly diphosphorylated (not depicted). Therefore, these results 
indicate that although both ERK1c and ERK1/2 are activated by 
MEKs (Aebersold et al., 2004; Yoon and Seger, 2006) they are 
subjected to different modes of regulation in mitotic cells.
It was previously reported that monophosphorylated 
ERK–like proteins are present in the Golgi just before fragmen-
tation (Cha and Shapiro, 2001). Indeed, staining of cells in 
  prophase or interphase confi  rmed the reported appearance of 
monophosphorylated ERK in mitosis, without an accompanied 
accumulation of diphosphorylated ERK in the Golgi under any 
conditions examined (Fig. 4 B). This staining experiment also 
revealed that the monophosphorylated ERK colocalized with 
ERK1c but not with ERK1/2, supporting the possibility that the 
monophosphorylated ERK in the mitotic Golgi is ERK1c.
Because our results indicate that ERK1c is activated by 
MEKs, we examined whether, unlike the diphosphorylation of 
ERK1/2 (Yoon and Seger, 2006), MEK1 phosphorylates ERK1c 
preferentially on its regulatory Tyr residue. Therefore, we ex-
amined the possibility that ERK1c, which is not recognized by 
most general ERK (gERK) antibodies but can be identifi  ed by 
the monophosphorylated ERK antibody, is the monophosphoryl-
ated ERK in the mitotic Golgi. To do so, we immunoprecipi-
tated MEK1-GFP from EGF-treated cells and, in parallel, we 
purifi  ed recombinant GST-ERK1c or GST-ERK1 from bacteria.   
Incubation of the active MEK1 with ERK1c in the presence 
of ATP and magnesium resulted in a fast accumulation of 
Figure 2.  Nocodazole treatment induces ERK1c expression and activation. 
(A) Nocodazole arrests HeLa cells in the G2/M phase of the cell cy- 
cle HeLa cells were either treated with 100 ng/ml nocodazole (M) for 24 h 
or left untreated as control (N). The cells were then ﬁ   xed, stained with 
propidium iodide, and analyzed by ﬂ   ow cytometry to determine the 
amount of DNA per cell (2N and 4N, as indicated). (B) Nocodazole-
  dependent mitotic arrest induces ERK1c activation. HeLa cells were treated 
with nocodazole (M) or left untreated (N). ERK1c and ERK1 were immuno-
precipitated from these cells using their respective COOH-terminal anti  -
bodies and either subjected to an in vitro kinase assay (Kinase act.) or 
Western blot with gERK antibody. In addition, the cell extracts were either 
subjected to Western blot (left, bottom middle, and bottom) or immunopre-
cipitated with ERK1c antibody followed by Western blot (right, bottom 
  middle, and bottom) with pERK or ERK1c antibodies (right, bottom middle, 
and bottom). (C) Quantiﬁ   cation of kinase activation. Fold activation of 
ERK1c and ERK1 was quantiﬁ  ed by densitometry and presented as means 
± SEM. n = 3.MITOTIC GOLGI FRAGMENTATION IS REGULATED BY ERK1C • SHAUL AND SEGER 889 
monophosphorylated ERK1c (Fig. 4 C) that was much faster 
than the appearance of pERK1c that correlated with the low 
activity of the kinase. Under these conditions, the diphosphoryl-
ation of ERK1/2 was much faster than the mono-Tyr phosphoryl-
ation, which is in agreement with previously published studies 
(Yao et al., 2000; Yoon and Seger, 2006). These results indicate 
that MEKs phosphorylate ERK1c preferentially on its Tyr204 
and suggest that the monophosphorylated ERK in the Golgi 
can be ERK1c, which is directly mono-Tyr phosphorylated by 
MEKs. Therefore, the presence of monophosphorylated ERK1c 
in the Golgi does not seem to require the activity of the Ser/
Thr phosphatase PP2A, which had previously been suggested 
Figure 3.  The subcellular localization of ERK1c during mitosis. Synchronized HeLa cells 11 h after the double thymidine block release were ﬁ  xed and 
stained with ERK1c, GM130 or p58 antibodies, and DAPI. Cells from interphase, prophase, prometaphase, metaphase (A), and telophase (B) were 
  selected by their DNA structure, which was observed using DAPI staining. Similar results were detected with at least 20 distinct cells for each condition. 
(C) ERK1 does not translocate to the Golgi during mitosis. HeLa cells were ﬁ  xed and stained with ERK1, GM130 or p58 antibodies, and DAPI. Cells in pro-
phase were selected by their DNA structure, which was observed using DAPI staining. Similar results were detected with at least 20 distinct cells for each 
condition. (D) Quantiﬁ  cation of ERK1c colocalization in the Golgi during mitosis. The percentage of mitotic or interphase cells in which ERK1c was colocalized 
with the Golgi markers was determined by counting 200 cells in each slide. The results in the bar graph represent the mean ± SEM of three experiments. 
Bars, 10 μm.JCB • VOLUME 172 • NUMBER 6 • 2006  890
as a potential cause for the presence of monophosphorylated 
ERK because of its activity on the phosphorylated Thr of di-
phosphorylated ERK-like protein in the Golgi   (Hancock et al., 
2005). The observation that monophosphorylated ERK1c was 
identifi  ed only in the Golgi, although it was also localized to 
some extent in other parts of the cytosol, suggests that the regu-
lation of this enzyme in the Golgi is distinct from its regulation 
in other cellular locations.
Figure 4.  ERK1c is activated by MEKs and is 
mainly mono-Tyr204 phosphorylated. (A) Mi-
totic ERK1c is either mono-Tyr phosphorylated or 
diphosphorylated and is activated downstream 
of MEKs. HeLa cells were transfected with 
CA-MEK (∆N-EE-MEK1, marked as MEK) or 
with GFP control. The cells were then synchro-
nized by double thymidine block and 
  released for 11 h. 25 μM PD98059 was 
added to one of the GFP plates (PD) 9 h after 
release, and the other GFP plate was left 
  untreated (Con). After harvesting, ERK1c was 
immunoprecipitated and either subjected to an 
in vitro kinase assay (ERK1c act.) or to a West-
ern blot with pERK, monophosphorylated ERK, 
and ERK1c antibodies. Coomassie blue stain-
ing of the MBP is shown as a control for equal 
substrate amounts. (B) ERK1c colocalizes with 
monophosphorylated ERK during mitosis. The 
synchronized HeLa cells were ﬁ  xed  and 
stained with ERK1c, ERK1, pY-ERK or pERK anti-
bodies, and DAPI. Cells from interphase and 
prophase were   selected by their DNA struc-
ture, which was   observed using DAPI staining. 
Similar results were detected with at least 
20 distinct cells for each condition. Bar, 5 μm. 
(C) ERK1c   undergoes preferential phosphoryl-
ation on its Tyr204. HeLa cells were transfected 
with MEK1-GFP. The cells were serum starved 
for 16 h and then stimulated with 50 ng/ml 
EGF for 3 min. MEK1-GFP was immunoprecipi-
tated and used to phosphorylate puriﬁ  ed GST-
ERK1c or GST-ERK1 for the indicated times. 
The amount of ERK1c and ERK1, as well as 
their phosphor  ylation, were determined by 
Western blotting using pY-ERK, pERK, and 
ERK1   antibodies. The results in the graphs 
  represent the mean and SEM of three experi-
ments. Squares represent diphosphorylation 
and   circles represents monophosphorylated 
ERK1 or ERK1c. MITOTIC GOLGI FRAGMENTATION IS REGULATED BY ERK1C • SHAUL AND SEGER 891 
ERK1c regulates Golgi fragmentation
Our results clearly indicated that ERK1c is localized and ac-
tive in the Golgi during mitosis, but its exact role there was not 
resolved. Therefore, we undertook to study whether ERK1c is 
the enzyme that participates in the regulation of mitotic Golgi 
fragmentation downstream of MEKs. To this end, we altered 
ERK1c (and ERK1 as control) expression in the mitotic cells by 
either overexpressing the GFP-conjugated wild-type constructs 
(68 and 70 kD of GFP-ERK1c and GFP-ERK1, respectively; 
Aebersold et al., 2004) or by knocking down the expression of 
the endogenous proteins using specifi  c small interfering RNA 
(siRNA). To confi  rm a specifi  c reduction of either ERK1c or 
ERK1, the interfering sequences were directed toward the unique 
COOH-terminal sequences of the ERKs. Indeed, expression of 
the ERK1c-interfering sequence (siRNA of ERK1c [si-ERK1c]) 
in HeLa cells, resulted in a reduction of 75 ± 7% in the expres-
sion of endogenous ERK1c, with no effect on the expression of 
ERK1/2 (Fig. 5 A).  Similarly, expression of the ERK-interfering
sequence (si-ERK1) specifi  cally reduced the expression of 
ERK1 (80 ± 10%) without any effect on ERK1c or ERK2. The 
reduction in ERK1c expression by its interfering sequence was 
also demonstrated by immunostaining with ERK1c antibody 
(Fig. 5 B), which showed a marked reduction in the amount 
of ERK1c with no signifi  cant change of its localization in the 
si-ERK1c–expressing cells (Fig. 5 B and Fig. S4, available at
http://www.jcb.org/cgi/content/full/jcb.200509063). It should 
also be noted that this correlation between the Western blot and 
the immunostaining confi  rmed the specifi  city of ERK1c staining 
by the antibody used in this study. As expected, activity assays 
showed that overall ERK1c activity in mitotic cells overexpress-
ing GFP-ERK1c was signifi  cantly higher than the activity derived 
from vector control cells, whereas the activity derived from the 
cells transfected with si-ERK1c was markedly lower (Fig. 5 C).
Therefore, this system was judged suitable for the study of 
downstream effects that are mediated either by phosphorylation 
or by changes in expression and localization of ERK1c.
To determine whether ERK1c is indeed involved in the 
regulation of Golgi fragmentation, we used both GM130 and 
p58 markers to follow Golgi architecture in cells expressing 
GFP, GFP-ERK1c, and si-ERK1c. In these experiments, the 
ERK1c constructs clearly affected Golgi fragmentation during 
interphase and the different stages of mitosis (Fig. 6).  Thus, in 
interphase, overexpression of ERK1c increased Golgi fragmen-
tation as previously reported (Aebersold et al., 2004), whereas 
the si-ERK1c had no signifi  cant affect (Fig. 6 A).  Acceleration 
of Golgi fragmentation by cells overexpressing ERK1c was also 
observed in prophase and to some extent in prometaphase, when 
the Golgi appeared much more broken than in cells transfected 
with GFP control. In these stages of mitosis, si-ERK1c expres-
sion signifi  cantly attenuated fragmentation, as only few Golgi 
Figure 5.  Modulation of ERK1c expression and activity 
with siRNA and GFP-ERK1c. (A) Speciﬁ  c  knockdown 
of ERK1c and ERK1 by their corresponding siRNAs. HeLa 
cells were transfected with GFP together with either 
a   plasmid containing si-ERK1c, a plasmid containing 
si-ERK1, or additional GFP (Con). 72 h after transfection, 
the cells were harvested and subjected to a Western blot 
with ERK1c and ERK1/2 (αgERK) antibodies. (B) si-ERK1c 
  reduces the amount of ERK1c in transfected cells. HeLa 
cells were cotransfected with si-ERK1c and GFP, and 72 h 
after transfection the cells were ﬁ   xed and stained with 
αERK1c antibody and DAPI. Bar, 30 μM. (C) Modulation in 
ERK1c expression correlates with its MBP phosphorylation. 
HeLa cells were transfected with pEGFP (Vector), si-ERK1c, 
or GFP-ERK1c (ERK1c) synchronized by double thymidine 
block and release for 11 h. After harvesting, ERK1c was 
immunoprecipitated from the cells and was   either sub-
jected to an in vitro kinase assay (ERK1c act.) or Western 
blot   using ERK1c antibody. Coomassie blue staining of the 
MBP conﬁ  rmed equal substrate.JCB • VOLUME 172 • NUMBER 6 • 2006  892
fragments could be detected in most of the cells (quantifi  ed in 
Fig. 6 A, right bottom).
We next followed the Golgi architecture in metaphase, 
when the Golgi markers appeared to be spread throughout the 
GFP control cells (Fig. 6 B), indicating that the Golgi was 
 completely fragmented, as expected (Colanzi et al., 2003). Interest-
ingly, the overexpression of GFP-ERK1c did not change the 
distribution of the Golgi markers. However, in 55% of the 
siRNA-expressing cells the Golgi was not completely spread, 
but was rather broken into bulbs that were still concentrated in 
Figure 6.  Modulation of ERK1c expression 
affect Golgi fragmentation during mitosis. 
HeLa cells were transfected with GFP, GFP-
ERK1c (ERK1c), or si-ERK1c with GFP (si-ERK1c). 
The cells were synchronized by double thymi-
dine block, and 11 h after the release were 
stained with GM130 or p58 antibodies and 
DAPI. (A) si-ERK1c and GFP-ERK1c affect 
Golgi architecture during prophase and pro-
metaphase. Cells from interphase, prophase, 
and prometaphase were selected by their 
DNA structure. The percentage of cells with 
fragmented Golgi apparatus is presented as 
means ± SEM of three experiments. n = 40. 
(B) Knockdown of ERK1c attenuates the forma-
tion of Golgi haze in metaphase. Cells in meta-
phase were selected by their DNA structure. 
The percentage of cells with big vesicles out of 
total metaphase cells is presented as means ± 
SEM of three experiments. n  = 40 cells. 
(C) Knockdown of ERK1c results in unequal 
Golgi division. Telophase cells were selected 
by their DNA structure. The percentage of cells 
with unequal Golgi division from total telo-
phase cells is presented as means ± SEM 
of three experiments. n = 40. Bars: (A and C) 
10 μm; (B) 5 μm.MITOTIC GOLGI FRAGMENTATION IS REGULATED BY ERK1C • SHAUL AND SEGER 893 
the cytoplasm, similar to its appearance in control prophase 
cells. Thus, si-ERK1c signifi  cantly inhibited Golgi fragmenta-
tion in the prophase/metaphase stages of the cell cycle. In telo-
phase (Fig. 6 C), the Golgi was already rebuilt and equally 
divided between the daughter cells in the GFP- and ERK1c-
  expressing cells, whereas in the si-ERK1c cells the division of 
Golgi between the daughter cells was not equal. In these cul-
tures, 60% of cell pairs had one cell with a bigger Golgi, whereas 
Figure 7.  Effects of ERK1c on mitotic progression. 
(A) Modulation of ERK1c expression affects cell cycle 
progression. HeLa cells were transfected with GFP, 
GFP-ERK1c, (ERK1c), si-ERK1c together with GFP 
(si-ERK1c), GFP-ERK1 (ERK1), and si-ERK1 together 
with GFP (si-ERK1). The cells were synchronized by 
dou  ble thymidine block as in Fig. 6. At the indicated 
times, the cells were ﬁ   xed, stained with propidium 
  iodide, and analyzed by ﬂ   ow cytometry for DNA 
  content (2N or 4N). (B) Effect of MEK activity on cell 
cycle progression. HeLa cells were transfected with 
  either GFP (GFP and PD98059) or with CA-MEK1 
(CA-MEK). The cells were synchronized by double-
  thymidine, as in Fig. 6. 25 μM PD98059 was added 
to one of the GFP plates (PD98059) 2 h before ﬁ  xa-
tion, whereas the other GFP plate was left untreated 
as  control. At the indicated times, the cells were 
ﬁ   xed, stained with propidium iodide, and analyzed 
by ﬂ  ow cytometry for their DNA content (2N or 4N). 
(C) Quantiﬁ  cation of the effect of the various  treatments. 
The ratio between G1/G2 was compared with 
that of the control cells. The results are means ± 
SEM of three experiments. A t test was used for statis-
tical analysis (*, P < 0.01). (D) Determination of 
  mitotic   index and percentage of cells in telophase. 
HeLa cells were transfected and synchronized as in A, 
and stained with DAPI. The percentage of   mitotic 
cells (left, Mitosis)   and cells at telophase out of the mi-
totic cells (right, Telophase) is presented in the bar 
graph as the means ± SEM of three experiments. 
n = 200 cells each. A t test was used for analysis. 
*, P < 0.05; **, P < 0.01.JCB • VOLUME 172 • NUMBER 6 • 2006  894
the Golgi of the mate cell was much smaller. These results could 
be a consequence of the incomplete fragmentation of the Golgi 
at metaphase that allowed a distribution of some unprocessed 
Golgi bulbs. These results may also suggest that the pace of mi-
totic progression is not fully synchronized with or controlled by 
Golgi fragmentation, as previously suggested (Uchiyama et al., 
2003). As expected from previous studies involving overexpres-
sion of ERK1 (Aebersold et al., 2004) and the absence of ERK1 
from mitotic Golgi (Fig. 3), ERK1 had no signifi  cant effect on 
Golgi architecture under any of the conditions used (Fig. S5, 
available at http://www.jcb.org/cgi/content/full/jcb.200509063; 
and not depicted), again supporting the specifi  c role of ERK1c 
in the regulation of Golgi fragmentation.
ERK1c regulates mitotic progression
Golgi fragmentation was found to play a critical role in the pro-
gression of mitosis (Sutterlin et al., 2002). Therefore, it was im-
portant to examine whether ERK1c regulates G2/M progression 
via its involvement in Golgi breakdown. To this end, HeLa cells 
overexpressing GFP only, GFP-ERK1c, GFP-ERK1, si-ERK1c, 
or si-ERK1 were synchronized using the double thymidine 
block, and examined by FACS for their cell cycle stage. Thus, 9 h 
after block release the various transfected cells were found in the 
G2 phase of the cell cycle, indicating that neither ERK1c nor 
ERK1 play a role in S/G2 progression of HeLa cells (Fig. 7 A).   
On the other hand, 11 h after release the GFP-ERK1c, but not 
GFP-ERK1, had a marked infl  uence on the mitosis progression 
(Fig. 7 A). As expected, the control GFP-expressing cells were 
reproducibly found equally in their 2N or 4N forms, indicating 
that most cells are in the midst of mitosis at this stage. Over-
expression of ERK1c shifted this distribution toward G1 (28% 
in G2 and 66% in G1; quantifi  cation in Fig. 7 C), whereas the 
si-ERK1c inhibited the transition (72% in G2 and 22% in G1). 
These effects were restricted to 10–12 h after release from the 
double thymidine block because when these experiments were 
performed 13 h after the release the cells were all found in the 
next G1 phase with no signifi  cant effect of any of the ERK con-
structs. These results indicate that the effect of ERK1c is re-
stricted to the initial stages of mitosis and is not mimicked by 
ERK1. Interestingly, the effects of ERK1c during mitosis were 
similar to those obtained by either inhibiting or activating the 
upstream kinase MEK1 (Fig. 7 B, 11 h). However, unlike 
ERK1c, the modulation of MEKs activity still maintained a mi-
nor, but signifi  cant, effect 13 h after release. Thus, PD98059 re-
tained 31% of the cells in G2 as compared with 12% observed 
in GFP control, and the CA-MEK1 reduced the percentage of 
cells in G2 to 7%. The longer effect of the MEKs inhibitor, as 
compared with si-ERK1c, may suggest that MEKs operate in 
part via Golgi-independent mechanisms to regulate the progres-
sion of mitosis (Roberts et al., 2002).
To further establish the mitotic role of ERK1c and MEKs, 
we monitored the percentage of mitotic cells 11 h after the dou-
ble thymidine release, as well as the percentage of cells in telo-
phase, out of the total mitotic cells. The percentage of mitotic 
cells was not affected by si-ERK1c expression (Fig. 7 D, left), 
but the percentage of cells in telophase was signifi  cantly inhib-
ited (Fig. 7 D, right), indicating again that ERK1c affects cell 
cycle at early stages of mitosis, without a signifi  cant effect on 
the G2 phase and the entrance to mitosis. The overexpression of 
ERK1c or CA-MEKs reduced the percentage of cells in mitosis 
but increased the portion of cells in telophase. This could be ex-
plained by the accelerated rate of mitotic progression in these 
cells, which pushed most of the cells to either telophase or to the 
G1 phase of the following cycle. Addition of PD98059 9 h after 
release from the double thymidine arrest inhibited the entrance 
and, even more so, the progression of cells in mitosis, indicating 
that unlike the si-ERK1c, it had some role at the G2/M phase, 
probably by its additional effect on ERK1/2. This conclusion is 
supported by the stronger effect of PD98059, when it was com-
bined with the release from the double thymidine arrest (not 
  depicted). Finally, the ERK1 constructs had no effects at these 
stages. These results further corroborate the specifi  c role of 
ERK1c in the progression of mitosis, which is probably attribut-
able to its effects on Golgi fragmentation at this stage.
Discussion
In this study, we show that ERK1c is an important regula-
tor of Golgi fragmentation during mitosis and thereby plays 
a role in controlling mitotic progression in human cells. 
Mitotic Golgi fragmentation is a two-step process in which the
 pericentriolar Golgi stacks are converted into bulbs and then 
either undergo further vesicular spreading or fuse with the ER 
(Colanzi et al., 2003). The fi  rst part of this process seems to 
be regulated by phosphorylation, which is mediated by sev-
eral protein kinases, including MEK1 (Acharya et al., 1998). 
The role of MEK1 in Golgi fragmentation was clearly dem-
onstrated in various cell types. However, the mechanisms by 
which MEK1 functions during this process was not clear be-
cause the known MEK1 substrates (ERK1/2) were not found 
to participate in the process (Acharya et al., 1998). Rather, it 
was suggested that mitotic MEKs may function via an ERK-
like protein (Acharya et al., 1998), which may be mono-Tyr 
phosphorylated (Cha and Shapiro, 2001), or via other protein 
kinases such as Plk3 (Xie et al., 2004).
In this study, we present data suggesting that ERK1c, but 
not ERK1/2, might be the mediator of the MEK-induced Golgi 
fragmentation during mitosis. This is strongly supported by the 
following observations: (a) the expression levels of ERK1c, 
but not ERK1/2, are elevated in late G2 and mitosis (Fig. 1); (b) 
the activity of ERK1c is elevated in late G2 and during mitosis 
(Fig. 1); (c) ERK1c, and not the other ERKs, is localized in the 
Golgi during the early stages of mitosis (Fig. 4); (d) si-ERK1c, 
but not of ERK1, reduces Golgi fragmentation during mitosis 
(Fig. 6), which attenuates mitotic progression (Fig. 7); and (e) 
ERK1c is preferentially phosphorylated on its Tyr204, which 
correlates with the appearance of pY-ERK in the mitotic Golgi 
(Fig. 3). This is unlike ERK1/2, which under most conditions 
are phosphorylated on both their activatory Thr and Tyr residues 
at a comparable rate (Fig. 4; Seger and Krebs, 1995; Yao et al., 
2000). This observation, together with the mitotic Golgi distri-
bution of ERK1c, strongly suggests that ERK1c is the mono-
phosphorylated ERK that was suggested to play a role in Golgi 
fragmentation during mitosis (Cha and Shapiro, 2001).MITOTIC GOLGI FRAGMENTATION IS REGULATED BY ERK1C • SHAUL AND SEGER 895 
It has previously been demonstrated that Golgi fragmenta-
tion is a crucial step in the progression of mitosis, and it was 
suggested that this fragmentation, in fact, provides a sensor for 
controlling entry into mitosis in mammalian cells (Sutterlin 
et al., 2002). Our results demonstrate that, indeed, inhibition of 
Golgi fragmentation achieved with the si-ERK1c caused a de-
lay in the onset of mitosis. However, the block was never full 
and could not be detected 13 h after the double thymidine 
  release. The incomplete arrest of the HeLa cells in mitosis could 
be caused by an incomplete inhibition of ERK1c activity be-
cause of the partial effect of the siRNA. However, it is also pos-
sible that Golgi fragmentation is not the only sensor for mitotic 
progression. This suggestion is supported by the observation 
that in cells expressing si-ERK1c, the distribution of Golgi frag-
ments to daughter cells during telophase was not equal (Fig. 6 C). 
Therefore, it is possible that the progression through mitosis 
is governed by a multistep mechanism, which requires Golgi 
  fragmentation at only one point during mitosis. Thus, partial
Golgi breakdown (such as the one observed in si-ERK1c pro-
metaphase in Fig. 6) is probably a suffi  cient signal to allow the 
mitotic progression. Because some of the Golgi membranes 
were still in bulb form and not in spread vesicle form, and the 
cells proceeded through telophase without waiting for the Golgi 
to complete its breakdown, an unequal distribution of particles 
resulted, and thus, an unequal Golgi size in the daughter cells. 
Interestingly, the cells overexpressing GFP-ERK1c contained 
similar amount of Golgi fragments in the daughter cells, al-
though the progression through early mitosis was accelerated in 
these cells. This indicates that once the Golgi is fully degraded 
it can be homogenously divided into the daughter cells at the 
right stage of mitosis. Therefore, our results may indicate that 
Golgi fragmentation is an important step in the initiation of 
  mitosis, but that once the set of events that are required for this 
progression have started, the synchronization of the process is 
probably regulated by other mechanisms.
ERK1c is an alternatively spliced form of ERK1, which is 
altered in the cytosolic retention sequence/common docking 
regulatory region; therefore, many of its regulatory aspects are 
distinct from those of ERK1/2. Indeed, in a previous study we 
showed that the kinetics of activation of this protein is distinct 
from its relative ERKs upon EGF or NaCl stimulation (Aebersold 
et al., 2004). Furthermore, the subcellular localization of ERK1c 
seems to be distinct from that of ERK1/2, as it was found 
mainly in the Golgi under various conditions (Fig. 3;  Aebersold 
et al., 2004). In our previous work, we suggested that the Golgi 
translocation of ERK1c is regulated by its monoubiquitination. 
In mitosis, this is probably not the situation, as we failed to ob-
tain ERK1c at any other molecular weight than the nonmodifi  ed 
endogenous 42-kD protein (Aebersold et al., 2004). Therefore, 
the mechanism that allows ERK1c to specifi  cally associate with 
the Golgi has yet to be clearly identifi  ed.
Additional information on ERK1c and ERK1 during mi-
tosis was observed using nocodazole, which arrests the HeLa 
cells in a prometaphase-like stage. Similar to cells synchronized 
by double thymidine block, nocodazole induced higher expres-
sion (Fig. 2) and Golgi localization (not depicted) of ERK1c, 
indicating that these effects are indeed mediated by cell cycle 
arrest and not by the individual effect of the drugs. However, de-
spite the pronounced activation of ERK1c after nocodazole treat-
ment (Fig. 2), which was higher than that observed upon double 
thymidine treatment (Fig. 1), the activation of ERK1 was much 
smaller (Fig. 1). This result is in agreement with a previous work, 
which showed that nocodazole does not induce ERK1 activation 
(Takenaka et al., 1998). The reason for the difference is not clear 
and could be the outcome of some nonspecifi  c effects of the cell 
cycle–arresting drugs. However, this difference could also be at-
tributable to the homogenous arrest of cells at the prometaphase-
like stage upon nocodazole treatment, unlike the wider cell cycle 
distribution in cells 11 h after release from double thymidine 
block (G2/anaphase). This may indicate that the activation of 
ERK1/2 occurs mainly during the G2–prophase stage and that 
this activity is reduced at prometaphase, whereas ERK1c is 
activated somewhat later than ERK1/2; its activity is maximal 
at prometaphase and may proceed even later in mitosis.
Importantly, the results of this study strongly suggest that 
ERK1c has unique functions that are not shared by ERK1/2 in 
regulating Golgi fragmentation. The functional difference be-
tween the isoforms was also manifested in the stronger block in 
cell cycle progression by the MEK inhibitor PD98059, as com-
pared with that of the si-ERK1c (Fig. 7). Because both si-ERK1c 
and PD98059 reduced ERK1c activity to a similar level (Figs. 4 
and 5), it is likely that MEKs have some ERK1c-unrelated ef-
fects on the progression of mitosis that are probably mediated by 
ERK1/2. This is supported by the fact that ERK1/2 are activated 
in the onset of mitosis as well (Fig. 1). In addition, ERK1/2 are 
not localized in the Golgi at any stage of the cell cycle, suggesting 
that they participate in other, Golgi-independent signaling events. 
The observation that reductions in ERK1 levels and activity did 
not exert any signifi  cant effect on the progression through mitosis 
(Fig. 7) may be explained by the ability of its close homologue 
ERK2 to compensate for its shortage. On the other hand, our re-
sults clearly indicate that ERK1c cannot overcome the effects of 
ERK1/2 and vice versa, which can be explained by their distinct 
localization and differential regulation (Aebersold et al., 2004). 
Thus, we propose a pathway in which activated MEKs colocal-
ize with ERK1c in the Golgi, activate it, and thereby induces the 
process of Golgi remodeling during mitosis. At the same time, 
other MEK molecules phosphorylate ERK1/2, and those mole-
cules participate in the regulation of distinct mitotic processes. 
Therefore, MEKs seem to orchestrate a large part of the mitotic 
events by activating three ERK isoforms that may each function 
in a different location and regulate distinct processes.
In summary, we characterized the function of ERK1c in 
the Golgi and found that it plays an important role in the regula-
tion of Golgi fragmentation during mitosis and thereby in the 
regulation of cell cycle progression. The ERK1c effects could 
not be complemented by ERK1/2, indicating that this isoform 
is the unique MEK effector in the mitotic Golgi. These results 
shed light on the MEK-dependent regulation of Golgi fragmen-
tation and division into the daughter cells during mitosis. 
In addition, this unique role of ERK1c extends the substrate 
specifi  city of the signaling by the ERK pathway and may sug-
gest a molecular mechanism for the ability of the ERK cascade 
to regulate distinct, and even opposing, cellular processes.JCB • VOLUME 172 • NUMBER 6 • 2006  896
Materials and methods
Reagents and antibodies
Thymidine, nocodazole, MBP, propidium iodide, EGF, and ATP were pur-
chased from Sigma-Aldrich. GM130, lamin A/C antibodies, and protein A/G
PLUS–agarose beads were obtained from Santa Cruz Biotechnology, Inc.
Sepharose-immobilized protein A, an ECL kit, glutathione beads, and 
γ[
32P]ATP were purchased from GE Healthcare. DAPI was purchased from 
Invitrogen, and PD98059 was obtained from Calbiochem. p58, pERK, 
  monophosphorylated ERK, gERK, and ERK1 antibodies were obtained from 
Sigma-Aldrich. The ERK1c antibody was prepared by the Antibody Unit 
of the Weizmann Institute of Science, as previously described (Aebersold 
et al., 2004). GFP antibody was purchased from Roche. The developing
substrate NBT/BCIP was obtained from Promega. FITC-, rhodamine-, 
alkaline phosphatase–, and horseradish peroxidase–conjugated secondary 
antibodies were obtained from Jackson ImmunoResearch Laboratories.
Buffers
Buffer A consists of 50 mM β-glycerophosphate, pH 7.3, 1.5 mM EGTA, 
1 mM EDTA, 1 mM DTT, and 0.1 mM sodium vanadate. Buffer H consists 
of Buffer A supplemented with 1 mM benzamidine, 10 μg/ml aprotinin, 
10 μg/ml leupeptin, and 2 μg/ml pepstatin A. Buffer RM (reaction mixture 
at threefold concentration) consists of 30 mM MgCl2, 4.5 mM DTT, 75 mM 
β-glycerophosphate, pH 7.3, 0.15 mM sodium vanadate, 3.75 mM EGTA, 
30 μM calmidazolium, and 2.5 mg/ml bovine serum albumin. Radio-
immunoprotein assay buffer consists of 137 mM NaCl, 20 mM Tris, 
pH 7.4, 10% (vol/vol) glycerol, 1% Triton X-100, 0.5% (wt/vol) deoxycho-
late, 0.1% (wt/vol) SDS, 2.0 mM EDTA, 1.0 mM PMSF, and 20 μM leu-
peptin. Buffer HNTG consists of 50 mM Hepes, pH 7.5, 150 mM NaCl, 
0.1%   Triton X-100, and 10% glycerol.
DNA constructs and siRNA
GFP-ERK and GFP-ERK1c were prepared in plasmid of EGFP (pEGFP) vec-
tor (Aebersold et al., 2004). CA-MEK1 (DN-EE-MEK1) was prepared in 
phosphorylated cDNA1 (Jaaro et al., 1997). GFP in pEGFP was purchased 
from CLONTECH Laboratories, Inc. GST-ERK1c was prepared by inserting 
ERK1c into the BamHI and EcoRI sites of pGEX-2T. The GST protein was 
puriﬁ   ed according to the manufacturer’s instructions and eluted from 
the glutathione beads using 10 mM of reduced glutathione. To generate the 
  pSUPER-ERK1c and pSUPER-ERK1 we used the pSUPER plasmid ( Brummelkamp 
et al., 2002). The sequence that was used (C  G  A  C  G  G  A  T  G  A  G  G  T  G  G  G  C  C  A  ; 
1,007–1,025 bp) was derived from the unique sequence of human ERK1c. 
For human ERK1, the sequence that was used (A  G  C  T  G  G  A  T  G  A  C  C  T  A  C  C  T  A  A  ; 
1,052–1,070 bp) was derived from the COOH terminus of human ERK1 
that is not present in ERK1c.
Cell culture and transfection
HeLa cells were grown in DME supplemented with 10% FCS (Invitrogen). 
Transfection into the cells was performed using the polyethylenimine 
method, as previously described (Boussif et al., 1995). In brief, the cells 
were grown to 50–70% conﬂ  uence in 12-well plates. The 1.5-μg plasmid 
was suspended in 125 μl PBS and mixed with polyethylenimine solution 
(5 μl of 3 mM polyethylenimine in 125 mM NaCl). The mixture was left at 
23°C for 15 min and then incubated with the cells for 90 min, after which 
the cells were washed and placed in DME + 10% FCS.
Immunoﬂ  uorescence microscopy
Cells were ﬁ  xed (20 min in 3% paraformaldehyde in PBS or 10 min in 
methanol at −20°C), followed by a 20 min permeabilization/blocking so-
lution (0.1% Triton X-100/2% BSA). Antibodies of choice were added for 
1 h, washed, and developed with ﬂ  uorescence-tagged secondary antibodies 
(Cy2, FITC, or rhodamine; Jackson ImmunoResearch Laboratories) for 1 h 
at 23°C. Nuclei were stained with 0.1 mg/ml DAPI (Invitrogen) in PBS. 
The slides were visualized using a ﬂ   uorescence microscope (Optiphot; 
Nikon) with 100×, 1.3 NA, or 40×, 0.7 NA, immersion oil objectives 
(Nikon). Digital images of cells were captured using a camera (DVC) and 
C-view V2.1 Imaging software (DVC). Images were processed using 
  Photoshop 7.0 (Adobe).
Preparation of cell extracts and Western blotting
After treatment, the cells were rinsed twice with ice-cold PBS and once with 
ice-cold buffer A. Cells were scraped into buffer H (0.5 ml per plate) and 
disrupted by sonication (two 50-W pulses for 7 s). The extracts were centri-
fuged (20,000 g for 15 min at 4°C) and the supernatants were kept at 4°C. 
The supernatants were then separated by a 10% SDS-PAGE, transferred 
onto a nitrocellulose membrane, and probed with the appropriate anti-
bodies, as previously described (Yao et al., 2000).
Immunoprecipitation
Cells extracts prepared as described in Cell culture and transfection were 
incubated (2 h at 4°C) with ERK1c (afﬁ  nity puriﬁ  ed), ERK1, or GFP anti-
bodies coupled to protein A/G–Sepharose. For determination of ERK1c 
activity, the beads were washed once with HNTG buffer, twice with 
0.5 M LiCl in 0.1 M Tris, pH 8.0, and once with 1 ml of buffer A. Immuno-
precipitates were subjected either to Western blotting or subjected to an 
in vitro kinase assay.
In vitro kinase assay
Immunoprecipitated ERKs attached to 15-μl beads were used as kinases by 
mixing them with MBP (8 μg/reaction). Similarly immunoprecipitated ac-
tive MEKs attached to 15-μl beads were mixed with either recombinant 
GST-ERK1c or GST-ERK1 (0.5 μg per reaction). Buffer RM containing 
100 μM γ[
32P]ATP (4,000 cpm/pmol) was added to the reaction at a ﬁ  nal 
volume of 30 μl and incubated for 20 min at 30°C. The reaction was 
  terminated by adding 10 μl of 4× sample buffer, and the phosphorylated 
proteins were resolved on SDS-PAGE and subjected to autoradiography 
and Western blot analysis with the proper antibodies.
Cell synchronization and FACS analysis
Cells were synchronized at the G1/S boundary by the double thymidine 
block (Merrill, 1998). In short, HeLa cells were treated with 2 mM thymi-
dine in DMSO, washed twice with PBS, grown for 8 h in regular medium, 
and then treated again with 2 mM thymidine for 16 h and washed with 
PBS. This marks time 0, after which the cells were grown under the regular 
conditions for the indicated times (Merrill, 1998). HeLa cells were also syn-
chronized at the M phase using 100 ng/ml nocodazole for 24 h (Merrill, 
1998). For FACS analysis, HeLa cells were trypsinized, washed with PBS, 
and ﬁ  xed in 70% ice-cold methanol for at least 1 h. The samples were then 
centrifuged (500 g for 2 min) and resuspended in 0.5 ml of staining solu-
tion (0.001% Triton X-100, 0.1 mM EDTA, 100 μg/ml RNase, and 
50 μg/ml propidium iodide in PBS). The cells were analyzed by FACsort 
(Becton Dickinson), and the percentage of cells at different stages was 
  calculated using the CellQuest software (BD Biosciences).
Online supplemental material
Fig. S1 shows the mitotic index of the synchronized cells. Fig. S2 shows 
that ERK1c translocation to the Golgi correlates with nuclear envelope 
breakdown. Fig. S3 shows the subcellular localization of ERK1c during 
mitosis (color images). Fig. S4 shows si-ERK1c in transfected cells. Fig. S5 
shows that ERK1 does not affect the Golgi architecture. Online supple-
mental material is available at http://www.jcb.org/cgi/content/full/
jcb.200509063/DC1.
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